Our mission is to Decode Biology to Radically Improve Lives. Through technologies like automation, new biological tools, and artificial intelligence, we believe we can generate intelligent maps of biology and navigate those maps to more effective medicines.
Historically, it has taken over ten years and an average capitalized R&D cost of approximately $2 billion per approved medicine to move a drug discovery project from early discovery to an approved therapeutic. This failure rate disappoints patients who are waiting for therapy and incurs huge costs that drive up drug prices.
Recursion Decoded tells the story of a new kind of pharma company. One that values big swings over cautious steps. One where the “Bilingual” workforce of “Recursionauts” is made up of a nearly equal balance of technologists and life scientists. And one where we won’t be satisfied with incremental improvements to the status quo. Read about how we are building the biopharma company of the future.
Our growing map of human cellular biology allows us to probe the complexity of disease and discover potential medicines by approaching drug discovery in a new way. This is the challenge we care so deeply about solving: finding better medicines and making them more accessible to the people who need them.
We aim to radically improve the lives of patients and those who love them. As we decode biology together, our collective efforts have the potential to bring about transformational change within biopharmaceutical industry norms - all while making lives profoundly better for patients around the world.
Our culture at Recursion is designed with intention to fuel our mission. We believe culture drives delivery. Essential to decoding biology in our context, is a mindset deeply committed to achieving impact at unprecedented scale through pioneering new industrialized approaches. We call it the Recursion Mindset.
The guideposts for teaching our people to successfully transition to TechBio and deliver our mission are our Founding Principles and Values.